Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | CNR1 | P21554 | 6/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 8/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450027 | 0.88 | BRD4 (0.44) | CNR2CNR1PPARA | |
| SCHEMBL13956434 | 0.88 | LTB4R (0.47) | TSHRCNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL4453277 | 0.88 | LTB4R (0.47) | TSHRCNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL4445408 | 0.85 | TSHR (0.41) | TSHRCNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL4445414 | 0.85 | TSHR (0.41) | TSHRCNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL4450025 | 0.84 | TSHR (0.36) | TSHRCNR2CNR1PPARA | |
| SCHEMBL4450879 | 0.83 | LTB4R (0.52) | TSHRCNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL4450768 | 0.83 | LTB4R (0.49) | TSHRCNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL13971111 | 0.83 | LTB4R (0.44) | TSHRLTB4RLTB4R2 | |
| SCHEMBL4450029 | 0.82 | CYSLTR2 (0.36) | TSHRCNR2CNR1LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583738-B1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-7482484-B2 | Carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | NR1H3, LDLR, NR1H2 | TSHR 53/4885CNR2 178/4885CNR1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.